TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is suffering from diarrhea or other signs or symptoms consistent with CDAD (as described in section 5.2.3)~* Presence of either toxin A or B (or both) of C. difficile in the stool within 24 hours prior to enrollment using the C. difficile Quik Chek Complete® diagnostic test, provided by the sponsor~Exclusion Criteria:~Subject will be excluded from participation if any of the following apply:~* Preterm neonates~* Negative C. difficile toxin test

- Gender: ALL
- Minimum Age: None
- Maximum Age: 27 Days
- Healthy Volunteers: f

Study Arms:
- Neonates (Type: None): Neonates with CDAD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NET of gastroenteropancreatic (GEP), pulmonary or unknown primary site origin~* Unresectable liver metastases, according the judgment of surgeon, (the reasons for the opinion of surgeon should be made explicit)~* Hepatic involvement ≤50% volume of the organ~* Radiological evidence of hepatic lesions (contemporaneous progression or appearance of extrahepatic lesions are allowed if not critical sites) that require change or initiation of systemic pharmacotherapy~* Patients undergoing , previously treated , or never treated with systemic medical therapy are eligible~* Patients with or without carcinoid syndrome are eligible~* Well (G1) or medium (G2) differentiated histology (according to WHO 2010 classification)~* Ki67 ≤ 20% (G1-G2)~* Life expectancy \> 6 months~* Age ≥ 18 and \< 80 years~Exclusion Criteria:~* Previous loco-regional post-surgical treatment~* Poorly differentiated histology~* Severe concomitant morbidities such as: severe coagulopathy, severe liver failure (to be detailed), renal failure (creatinine \> 2.0 mg/dl) and heart failure (NYHA 3-4 or unstable ischemic heart disease), contraindicating the interventional procedure or influencing the general prognosis (Investigator to provide details of exclusion)~* Extrahepatic metastasis in critical locations as: brain, spinal cord, lung with respiratory impairment, symptomatic vertebral lesions~* Patients with only extra-hepatic lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pharmacologic therapy (Type: ACTIVE_COMPARATOR): Patients in this arm receive systemic pharmacologic therapy alone
- TAE and pharmacologic therapy (Type: EXPERIMENTAL): Patients in this arm receive systemic pharmacologic therapy and TAE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Pilot Study Comparing Cost Effectiveness on Two Commercially Available Gastric Feeding Tubes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed an IRB-approved informed consent form for the study.~2. Adults (18-75 years of age)~3. Requirement of long term enteral tube feeding (\> to 12 months) and are due for a change of their initial or prior replacement bolus Percutaneous Endoscopic Gastrostomy (PEG) tube.~4. Ability to consent for the procedure and study.~5. Subjects must be able to communicate in english via telephone and understand the assessment checklists.~6. Expected to survive 12 months. Exclusion Criteria~The following subjects will not be eligible for inclusion in the study:~1. Enteral feeding is not necessary for at least 12 months,~2. A medical condition that makes it impossible for them to communicate via telephone~3. Subjects requiring feeding into the jejunum via a combined gastroenterostomy-jejunostomy tube~4. Subjects who require endoscopic replacement of their current gastrostomy tube.~5. Impaired cognition, inability to provide assessment feedback by telephone.~6. Subjects not expected to survive \> 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Capsule Dome G-Tube (Type: ACTIVE_COMPARATOR): Capsule Dome G-Tube
- Balloon Bolus feeding tube (Type: ACTIVE_COMPARATOR): Balloon Bolus feeding tube

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Pulmonary Arterial Hypertension (PAH) confirmed by cardiac catheterization.~* Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms.~Exclusion Criteria:~* Has portal hypertension or chronic liver disease.~* Has history of left sided heart disease or significant cardiac disease.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitaxsentan (Type: EXPERIMENTAL): Sitaxsentan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Nitrates and IL-8 in Barrett's Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients undergoing a clinicallly-indicated Esophagogastroduoedoscopy (EGD).~Exclusion Criteria:~* Comorbid inflammatory medical condition.~* Use of antiinflammatory (aspirin and NSAIDs) or immunosuppressants over the past 1 week.~* Use of nitrate containing medication in the past 1 week.~* Consumption of nitrate rich foods in preceding 24 hours.~* Known allergy to meat or nitrates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1-NSE (Type: None): Patients found to have grossly normal squamous epithelium during endoscopy
- Group 2-EEG (Type: None): Patients found to have grossly apparent erosive esophagitis \>1cm with Los Angeles Classification A-D
- Group 3-NDBE Short (Type: None): Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Short Segment)
- Group 4-NDBE Long (Type: None): Patients with non-dysplastic Barrett's Esophagus (NDBE) \> 1cm (Long Segment)
- Group 5 (Type: None): Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)
- Group 6-Esophagectomy (Type: None): Patients undergoing resection of esophageal cancer
- Group -7 Pilot and Feasibility (Type: None): Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ventilation in Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* out-of-hospital cardiac arrest (OHCA)~* cardio-pulmonary resuscitation (CPR) efforts~* endotracheal intubation~Exclusion Criteria:~* children and adolescents (age\<18 years at inclusion)~* pregnant women~* previous documented lack of legal capacity~* previous documented refusal to participate in trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Alternative Ventilation Rate (Type: ACTIVE_COMPARATOR): ventilation is performed at 20 breaths/min
- Conventional Ventilation Rate (Type: ACTIVE_COMPARATOR): ventilation is performed at 10 breaths/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation to Evaluate the Safety and Efficacy of Dressing CONNETTIVINA HI TECH in the Management of Superficial Cutaneous Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent.~* Male or female ≥ 18 and ≤ 85 years~* Having a superficial cutaneous lesion of different etiology, with the following characteristics:~Wound bed appearance of grade ≥15 of WBS (Wound Bed Score: Falanga 2006) Absence of clinical signs or symptoms of local infection (as defined by CDC/NHSN) Size: between 5 and 32 cm2 that can be covered by a dressing of 4x8cm~* In case of multiple lesions per patient, only one lesion will be considered for the treatment (the better choice for self-evaluation of lesion by patient)~* Patient able to maintain a Patient's Diary during the study~* Patient able to read and understand the language and content of the study material, understand the requirements for follow-up visits, is willing to provide information at the scheduled evaluations and is willing and able to comply with the study requirements~* Ensured compliance of subjects for the study period~Exclusion Criteria:~1. Patients who not sign the informed consent form~2. Patients with non-superficial wounds exposing bones, tendon or muscle bundles.~3. Patients with WBS score under or equal to 14 (severe exudate amount, or moderate exudate amount and moderate per-wound dermatitis or moderate callous peri-wound)~4. Presence of signs of infection as defined by CDC/NHMS~5. History of connective tissue disease, e.g., systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome or mixed connective tissue disease~6. Uncontrolled congestive heart failure~7. Active malignant disease~8. Active sickle cell disease~9. Patients who are immunocompromised for reasons such as therapy with corticosteroids, chemotherapy, antiangiogenic or immunosuppressive agents, or due to immunodeficiency syndromes~10. Known allergy to any of the devices' constituents~11. Women who are pregnant, breastfeeding or who have not reached menopause and are not abstinent or practicing an acceptable means of birth control as determined by the Investigator for the duration of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CONNETTIVINA HI TECH patch (Type: EXPERIMENTAL): CONNETTIVINA HI TECH patch will be applied to eligible patients. CONNETTIVINA HI TECH will be renewed every two day, according with general principles of wound management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-emergency aortic valve replacement with a biological prosthesis with perfusion and cardiac arrest~Exclusion Criteria:~* Recent myocardial infarction~* Carotid stenosis requiring intervention~* Any other concomitant surgical procedure~* Increased troponin baseline before surgery~* Critical ischemia of lower limbs~* Peripheral arterial disease (ASO, media sclerosis)~* Morbid obesity (Incompatible cuff-to-thigh diameter)~* Severe heart insufficiency~* Moderate to severe venous insufficiency lower limbs~* Recent acute stroke \<90d~* Difference in cardioplegic protocol~* Diseased aorta in epiaortic ultrasound

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remote ischemic preconditioning (Type: EXPERIMENTAL): Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
- Control group (Type: NO_INTERVENTION): Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the ECHELON Contour Curved Cutter Stapler Device in Colorectal Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elective colorectal procedure where Echelon Contour is planned to be used for transection and resection of the colon~* Willingness to give consent and comply with all study-related evaluations and visit schedule. If the participant is less than (\<) 18 years of age, the participant's parent/legal guardian must be willing to give permission for the participant to participate in the study and provide written Informed Consent for the participant. In addition, assent must be obtained from pediatric participants who possess the intellectual and emotional ability to comprehend the concepts involved in the study. If the pediatric participant is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the study); the parent/legal guardian's written Informed Consent for the participant will be acceptable for the participant to be included in the study~* Anatomical region must be of sufficient size for the device to be used~Exclusion Criteria:~Preoperative~* Females who are pregnant~* Physical or psychological condition which would impair study participation~* Participant previously enrolled into the study (example: participant enrolled for Hartmann's procedure then cannot be reenrolled for the Hartmann's reversal)~Intraoperative~- Study device use not attempted

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Echelon Contour (Type: None): This prospective study will include the participants who plan to have an elective colorectal surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the Echelon Contour instruction for use (IFU).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e., lumpectomy)~Exclusion Criteria:~* Children (\< 18 years old)~* Pregnant or Lactating women~* Diabetic patients (Type I or II)~* Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM~* Patients who have NOT undergone a standard of care bilateral breast MRI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Beast cancer subjects (Type: EXPERIMENTAL): Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* About to initiate or currently being treated with abiraterone acetate 1000 mg orally once daily~* Clinically able to receive abiraterone acetate in the opinion of the investigator in accordance with standard prescribing practices~* Ability to consume a low fat and high fat diet~* Expected duration of continuous abiraterone therapy \> 8 weeks~* Signed and dated informed consent~Exclusion Criteria:~* Patients taking medications that strongly inhibit or induce cytochrome P450 (CYP)3A4 within 28 days prior to the start of the study will be excluded

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (abiraterone acetate, low then high fat breakfast) (Type: EXPERIMENTAL): Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
- Arm II (abiraterone acetate, high then low fat breakfast) (Type: EXPERIMENTAL): Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* have a diagnosis of SCD (any genotype)~* report significant depression or anxiety symptoms (i.e., Patient Health Questionnaire \[PHQ-9\] or Generalized Anxiety Disorder Scale \[GAD-7\] \> 4)~Exclusion Criteria:~* Unable to read English or understand the consent process~* Cognitively impaired adults as determined by their treating physician~* Any condition that in the opinion of the investigator would not allow the patient to continue on the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- off-the-shelf digital CBT (Type: ACTIVE_COMPARATOR): standard implementation strategy that has no content or references to SCD, chronic pain, or the unique challenges facing minority groups
- adapted digital CBT (Type: EXPERIMENTAL): has content or references to SCD, chronic pain, and the unique challenges facing minority groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of TFP, or LCHAD deficiency and progressive peripheral neuropathy~* Subjects must be \> 7 years of age, and be willing to take vitamin E supplements.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCHAD/TFP with peripheral neuropathy (Type: EXPERIMENTAL): Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 Years or older~* Males or Females~* Primary diagnosis of TBI, subarachnoid hemmorhage (SAH), intracranial hemmorhage (ICH), stroke~* Requires mechanical ventilation~* Requires or is receiving continuous IV sedation~Exclusion Criteria:~* Glascow Coma Score (GCS) of 3 persisting from the scene with bilaterally fixed dilated pupils with no appreciable chance of survival~* The inability to identify a next of kin or guardian to give consent if patient unable to consent~* Pregnant~* Allergy or contraindication to propofol~* Allergy to contraindication to midalozam~* Status epilepticus~* Current neuromuscular blockade~* Patient with a known hypersensitivity to propofol or midalozam~* Allergies to eggs, egg products, soybeans or soy products~* Acute narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous sedation with propofol (Type: ACTIVE_COMPARATOR): Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
- Intravenous sedation with midazolam (Type: ACTIVE_COMPARATOR): Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues